NCT01151904 - Study of Brimonidine and Timolol Ophthalmic Solution With Latanoprost Compared With Latanoprost in Glaucoma Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

February 29, 2012

Study Completion Date

February 29, 2012

Conditions

Glaucoma, Angle-Closure

Interventions

DRUG

brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution

COMBIGAN® (brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution) administered as one drop in the morning and one drop in the evening in affected eye(s) for 12 weeks.

DRUG

latanoprost

Latanoprost administered in the affected eye(s) as prescribed by physician.

Trial Locations (1)

Unknown

Bangkok